标题：非编码RNA：支架内再狭窄治疗策略的新靶点

      作者：杨双亚 综述 邓文文，石蓓 审校    遵义医科大学附属医院心血管内科，贵州 遵义 563000

      卷次： 2020年31卷4期

      【摘要】 冠心病(CAD)近年来发病呈年轻化趋势，已成为威胁人类健康的主要疾病之一。经皮冠脉介入手术(PCI)是目前主要的治疗方法。然而，支架作为一种外源性物质，会引起血管平滑肌细胞增殖、炎症反应、免疫反应和新生内膜形成，进而导致支架内再狭窄(ISR)和晚期血栓形成，严重影响冠心病支架植入患者预后。非编码核糖核酸(ncRNAs)是不翻译蛋白质的RNA，研究表明其在调节内皮细胞、平滑肌细胞功能及炎症反应方面具有巨大的潜力。本文概述了不同类型的ncRNAs在支架内再狭窄过程中的调控作用，并提出ncRNAs可作为支架内再狭窄治疗的新靶点。
      【关键词】 非编码RNA；冠状动脉疾病；支架内再狭窄；微小RNA；长链非编码RNA；免疫反应；炎症反应
      【中图分类号】 R541.4 【文献标识码】 A 【文章编号】 1003—6350（2020）04—0507—05

Non-coding RNA: a new target for in-stent restenosis treatment strategies.
YANG Shuang-ya, DENG Wen-wen, SHIBei. Department of Cardiology, Affiliated Hospital of Zunyi Medical University, Zunyi 563000, Guizhou, CHINA【Abstract】 Coronary heart disease (CAD) is becoming younger in recent years and has become one of the maindiseases threatening human health. Percutaneous coronary intervention (PCI) is the main treatment at present. However,stent, as an exogenous substance, can cause vascular smooth muscle cell proliferation, inflammatory reaction, immune re-sponse and neointimal formation, resulting in stent restenosis (ISR) and late thrombosis. It seriously affects the prognosisof patients with coronary heart disease after stent implantation. Non-coding ribonucleic acid (ncRNAs) does not code pro-teins. Studies have shown that ncRNAs have great potential in regulating the function and inflammatory response of endo-thelial cells and smooth muscle cells. In this review, we summarize the regulatory role of different types of ncRNAs in theprocess of in-stent restenosis, and propose that ncRNAs can be used as a new target for the treatment of in-stent restenosis.
      【Key words】 Non-coding RNA; Coronary artery disease; In-stent restenosis; MicroRNA; Long non-codingRNA; Immune response; Inflammatory response·综述·doi:10.3969/j.issn.1003-6350.2020.04.027基金项目：国家自然科学基金地区项目(编号：81860063)；贵州省科技合作计划项目(编号：黔科合LH【2015】7512号)